SIC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C

Romero-Gómez, M.; Montes-Cano, M. A.; Otero-Fernández, M. A.; Torres, B.; Sánchez-Muñoz, D.; Aguilar, F.; Barroso, N.; Gómez-Izquierdo, L.; Castellano-Megias, V. M.; Núuñez-Roldán, A.; Aguilar-Reina, J.; González-Escribano, M. F.
March 2004
Gut;Mar2004, Vol. 53 Issue 3, p446
Academic Journal
Background and aims: The solute carrier family 11 member 1 (SLC11A1) gene (formerly Nramp1) encodes for the protein solute carrier family 11, member 1. It affects susceptibility and clinical outcome of autoimmune and infectious diseases. We investigated the possible role of the functional polymorphism located in the promoter region of SLC11A1 and tumour necrosis factor (TNF) genes in the progression of fibrosis in chronic hepatitis C. Methods: A total of 242 Caucasian Spanish patients with biopsy proven chronic hepatitis C and 194 healthy control subjects were genotyped for SLC11A1 and TNF promoter polymorphisms. Results: No significant differences in the distribution of frequencies among patient and control groups were observed. The SCL11Al homozygous 2/2 genotype was rarely detected among patients showing advanced fibrosis (2/82; 2.4%) but was highly represented in those with mild fibrosis (29/160; 18.1%; odds ratio (OR) 8.85 (95% confidence interval (CI) 1.9-55.2, pc=0.002). In patients carrying allele 3 of SLC11A1, the presence of -238 TNF A/G was associated with advanced fibrosis (14/26 (53.8%) v 68/216 (31.4%); OR 2.53 (95% CI 1.03-6.23); p=0.02). Conclusions: SLC11A1 gene promoter polymorphism could influence fibrosis progression in chronic hepatitis C in that the homozygous genotype 2/2 exerts a protective effect against cirrhosis development. Also, the combination of TNF -238 A/G and the presence of allele 3 is conducive to progression to pre-cirrhotic or cirrhotic stages of the disease.


Related Articles

  • The CCR5-Δ32 mutation: impact on disease outcome in individuals with hepatitis C infection From a single source. Goulding, C.; Murphy, A.; MacDonald, G.; Barrett, S.; Crowe, J.; Hegarty, J.; McKiernan, S.; Kelleher, D. // Gut;Aug2005, Vol. 54 Issue 8, p1157 

    Background and aims: Chemokines are small polypeptides, a major function of which is lymphocyte recruitment and trafficking. The aim of this study was to assess the involvement of inherited variations in CCR2, CCR5, and the ligand RANTES in determining disease outcome in hepatitis C virus (HCV)...

  • Recombination in Hepatitis C Virus: Identification of Four Novel Naturally Occurring Inter-Subtype Recombinants. Shi, Weifeng; Freitas, Ines T.; Zhu, Chaodong; Zheng, Wei; Hall, William W.; Higgins, Desmond G. // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    Recombination in Hepatitis C virus (HCV) is considered to be rare. In this study, we performed a phylogenetic analysis of 1278 full-length HCV genome sequences to identify potential recombination events. Nine inter-genotype recombinants were identified, all of which have been previously...

  • Prevalence of hepatitis C virus (HCV) genotypes in Balochistan. Sarwat Afridi; Muhammad Naeem; Abid Hussain; Naseebullah Kakar; Masroor Babar; Jamil Ahmad // Molecular Biology Reports;Jul2009, Vol. 36 Issue 6, p1511 

    Abstract  A molecular study was conducted to investigate the prevalence of Hepatitis C virus genotypes in HCV infected population of Balochistan. Forty HCV seropositive samples belonging to seven different locations of Balochistan were collected from different health care centres....

  • Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations? Alsiö, Åsa; Christensen, Peer Brehm; Färkkilä, Martti; Langeland, Nina; Buhl, Mads Rauning; Pedersen, Court; Mørch, Kristine; Haagmans, Bart L.; Westin, Johan; Hellstrand, Kristoffer; Norkrans, Gunnar; Lagging, Martin // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, pe22 

    Twelve of 303 per-protocol patients were nonresponders in a 12-week versus 24-week treatment study of hepatitis C virus (HCV) genotype 2/3 infection. The nonresponders had significantly lower interferon concentrations, as well as significantly greater mean age, body mass index, and viral load....

  • Molecular epidemiology of hepatitis C infection in Cyprus within the general population and high-risk cohorts.  // BMC Research Notes;2011, Vol. 4 Issue 1, p468 

    The article presents a study investigating molecular epidemiology of hepatitis C virus (HCV) infection in Cyprus within the general population and high-risk groups. The subjects of the study include additional subjects from the general population which is a group of inmates and HIV/HCV...

  • Response of Combination Therapy on Viral Load and Disease Severity in Chronic Hepatitis C. Abdul Malik; Mohammad Asim; Anita Chakravarti; Rakha Das // Digestive Diseases & Sciences;Apr2008, Vol. 53 Issue 4, p1107 

    Abstract  Influence of genotypes on viral kinetics and disease severity in chronic hepatitis C (CH-C) patients has been implicated, but requires further investigation. The 41 HCV patients were genotyped by restriction fragment length polymorphism and included for 48 weeks...

  • Genotyping of hepatitis C virus by melting curve analysis with SYBR Green I. Fujigaki, Hidetsugu; Takemura, Masao; Takahashi, Kanako; Yamada, Yasuhiro; Fujii, Hidehiko; Wada, Hisayasu; Saito, Kuniaki; Ohnishi, Hiroo; Seishima, Mitsuru // Annals of Clinical Biochemistry;Mar2004, Vol. 41 Issue 2, p130 

    Background: Recent studies have focused on whether different hepatitis C virus (HCV) genotypes are associated with different profiles of pathogenicity, infectivity, and response to antiviral therapy. We needed to develop a convenient screening test for HCV genotypes 1 and 2. Method: We tested 55...

  • Late relapse after SVR may not be new HCV infection. Shafer, Emily // Infectious Disease News;Dec2013, Vol. 26 Issue 12, p17 

    The article reports that patients with hepatitis C who had relapse after gaining sustained virological response (SVR) may be having a relapse of the initial infection and not a reinfection with a different strain of the virus, according to a study by National Institute of Diabetes and Digestive...

  • Host genetic determinants in hepatitis C virus infection. Yee, L.J. // Genes & Immunity;Jun2004, Vol. 5 Issue 4, p237 

    In addition to viral and environmental/behavioural factors, host genetic diversity is believed to contribute to the spectrum of clinical outcomes in hepatitis C virus (HCV) infection. This paper reviews the literature with respect to studies of host genetic determinants of HCV outcome and...


Read the Article


Sign out of this library

Other Topics